


VITEK[®] 2

Microbiology
with confidence

Antifungal AST Card Improved time to result

In two studies of patients with *Candida* bloodstream infections, delays of 12-14 hours resulted in a mortality rate 2-3 times higher compared to patients who received more timely antifungal therapy.^{1,2}



Relationship between hospital mortality and the timing of antifungal treatment[†]

VITEK[®] 2 AST-YS08 Ref. 420739*

Amphotericin B

Caspofungin[†]

Fluconazole[†]

Flucytosine[†]

Micafungin[†]

Voriconazole

[†] New redeveloped versions

* Not available in the United States. Availability elsewhere pending local regulatory clearance.

**Based on clinical trial data.

Contact your bioMérieux representative for availability

VITEK[®] 2 AST-YS08 CARD OFFERS:

- 4 antifungals with improved performance^{6†}
- Results in as little as **6 hours****
- Reduced hands-on-time compared to other automated systems³⁻⁵
- Rapid, automated and standardized testing taking subjectivity out of antifungal AST

REFERENCES

- 1 - Morrell M, Fraser VJ, Kollef MH. Antimicrob Agents Chemother 2005; 49: page 3640-5.
- 2 - Garey KW, Rege M, Pai MP, et al. Clin Infect Dis 2006; 43:25-31.
- 3 - Blondel-Hill E., Jang W., Lee I., Borton N., Book L., Thomas E. ICAAC 2006; Poster D-691.
- 4 - Heller-Ono A. bioMérieux White Paper, 2008.
- 5 - Hooper M., Hill C., Hadwell V., Blondel-Hill E. ECCMID 2013; Poster P-1536.
- 6 - Pfaller MA, Diekema DJ, Procopgw, Wiederhold NP. JCM 2014; 52(6):2126-2130